Lenalidomid Teva (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos. This action results in anti‑angiogenic, immunomodulatory, and anti‑proliferative effects that inhibit malignant cell growth and enhance immune-mediated tumor clearance.

The specific dose and schedule of Lenalidomid Teva are determined by the prescribing clinician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Healthcare providers tailor the regimen to achieve optimal therapeutic benefit while minimizing toxicity.

Lenalidomid Teva is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm. Women of childbearing potential must use effective contraception. The safety of the drug during breastfeeding has not been established, and nursing is generally discouraged.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory agent. Lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy, and provides stronger anti‑angiogenic activity. However, both drugs share risks such as thrombosis and myelosuppression, and the choice depends on individual patient factors.

Lenalidomid Teva should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in humid or excessively hot environments.

Lenalidomid Teva is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole with water and follow the dosing schedule provided by their healthcare professional.

The most serious risks include deep vein thrombosis or pulmonary embolism, severe neutropenia or leukopenia that can lead to infection, hepatotoxicity, and the potential development of second primary malignancies. Prompt reporting of symptoms such as unexplained pain, fever, or unusual bleeding is essential.

Lenalidomid Teva should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, patients with uncontrolled infections, or those with severe renal or hepatic impairment without appropriate dose adjustment. Clinicians must evaluate each patient’s medical history before initiating therapy.